Source-grounded facts extracted from NextCure, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NextCure, Inc.: Amendment to Certificate of Incorporation to effect a 1:12 reverse stock split (effective 2025-07-14).
“On July 14, 2025, NextCure, Inc., a Delaware corporation (the “ Company ”), effected a one-for-twelve (1:12) reverse stock split (“ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”).”
NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the cl”
Han Myint retired as Chief Medical Officer at NextCure, Inc..
“Dr. Han Myint, M.D. notified NextCure, Inc. (the “Company”) of his plan to retire from his position as Chief Medical Officer of the Company, effective July 1, 2024.”
NextCure, Inc. reported first quarter 2024 results: net income Net loss was $17.1 million.
“NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
NextCure, Inc. reported financial results for the year ended December 31, 2023.
“On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.